Expert's Video Prescribing Information Jardiance HF Previous Next Let's Talk - Impact of SGLT2i trials in HFpEF 01/07/2023 | Document ID: PC-PH-104987 PTPHF||JRDHF||Let's Talk - Impact of SGLT2i trials in HFpEF PTPHF||JRDHF||Let's Talk - Guidelines HFrEF Initiating Empagliflozin in HF patients with low eGFR Empagliflozin JARDIANCE improves QoL of HF patients Empagliflozin has consistent CV benefits in the full spectrum of HF Empagliflozin's robust renal data in the full spectrum of HF JRDHF||Empagliflozin's Proven Efficacy and safety in HF patients with or without T2D JRDHF||Renal efficacy and safety of Empagliflozin in HF JRDHF||How confident are you to start Empagliflozin to non-T2D HF patients? JRDHF||How effective is Empagliflozin with or without ARNI? RELATED CONTENT Read more 2:27 PTPHF||JRDHF||Let's Talk - Impact of early benefits Watch now Opens in new tab Read more 3:53 PTPHF||JRDHF||Let's Talk - SGLT2i as ideal therapy Watch now Opens in new tab Production Date: August 2023 Home Experts Video PTPHF||JRDHF||Let's Talk - Impact of SGLT2i trials in HFpEF
